A new technology developed at Tel Aviv University (TAU) makes it possible to destroy cancerous tumors in a targeted manner via a combination of ultrasound and the injection of nanobubbles into the bloodstream.
According to the research team, this latest technology enables the destruction of the tumor in a non-invasive manner, unlike invasive treatment methods or the injection of microbubbles into the tumor itself.
Accidental science is the best. One of the greatest lifesaving drugs in history – penicillin – was discovered purely by accident, and such experiments truly show how intricate and unpredictable science is.
So, when researchers from the University of Pennsylvania began their journey looking for a type 2 diabetes treatment and stumbled across a potentially incredible weight-loss treatment, needless to say, they were more than surprised.
The researchers describe their new results in a paper in the journal Science, in which they applied a treatment to a group of lab mice in the pursuit of counteracting type 2 diabetes. Instead of performing as expected, the experiment took a surprising turn – the mice started secreting a slimy substance through their skin.
Analysts and e-commerce leaders have been predicting a muted online holiday shopping season this year, with sales in the first three weeks of November essentially flat over a year ago due to a weaker economy, inflation, and more people returning to shopping in stores again in the wake of the Covid-19 pandemic. But on the face of it, the Thanksgiving long weekend appears to be more buoyant than expected — albeit growth has definitely slowed down this year after the pandemic-period boom.
Black Friday broke $9 billion in sales for the first time yesterday, with online sales of $9.12 billion, according to figures from Adobe Analytics. This is a record figure for the day, and up 2.3% on sales figures a year ago, and slightly higher than Adobe had estimated leading up to the day. Adobe doesn’t break out volumes in its report, so it’s hard to know if those figures are due to items simply costing more this year because of inflation, or if the higher numbers are a result of more buying.
Black Friday is a key focus for those gauging how the e-commerce market, and consumer confidence, are both faring in what is the most important and biggest period for shopping in the year.
In a study from Yale-NUS College, researchers found evidence that metabolic dysfunction is a primary cause of Alzheimer’s disease is the most common neurodegenerative disease affecting the elderly worldwide, as well as one of the most common causes of dementia. In Singapore, one in 10 people aged 60 or above is believed to suffer from dementia.
Researchers at Harvard University are investigating whether human genes could reverse the effects of aging. NBC Medical Fellow Dr. Akshay Syal got exclusive access to their lab to discuss the future of how to defy aging.
» Subscribe to NBC News: http://nbcnews.to/SubscribeToNBC
» Watch more NBC video: http://bit.ly/MoreNBCNews.
NBC News Digital is a collection of innovative and powerful news brands that deliver compelling, diverse and engaging news stories. NBC News Digital features NBCNews.com, MSNBC.com, TODAY.com, Nightly News, Meet the Press, Dateline, and the existing apps and digital extensions of these respective properties. We deliver the best in breaking news, live video coverage, original journalism and segments from your favorite NBC News Shows.
Connect with NBC News Online!
NBC News App: https://smart.link/5d0cd9df61b80
Breaking News Alerts: https://link.nbcnews.com/join/5cj/breaking-news-signup?cid=s…lip_190621
Visit NBCNews. Com: http://nbcnews.to/ReadNBC
Find NBC News on Facebook: http://nbcnews.to/LikeNBC
Follow NBC News on Twitter: http://nbcnews.to/FollowNBC
#NBCNews #Aging #Science
No questions concerning plasma dilution or E5, but a good interview with chapters.
Professor Matt Kaeberlein discusses the Dog Aging Project, longevity, Rapamycin, mTOR, and if we can ‘solve aging’
Timestamps:
0:00 Dog Aging Project.
4:18 Intermittent fasting.
10:23 Best longevity lifestyle.
16:25 Rapamycin & mTOR
23:27 Rapamycin human study.
30:18 Protein restriction diets.
39:46 Combination longevity therapies.
45:38 SGLT2i therapies.
47:23 Metformin & longevity.
52:50 Navigating misinformation.
55:28 Creatine.
59:00 Best exercises for longevity.
01:03:00 Can we solve aging?
01:09:45 Epigenetic reprogramming.
1:16:50 Supplements Dr Kaeberlein takes.
Donate towards our Rapamycin & Exercise clinical study: https://bit.ly/3QwugRx.
My full supplement stack: https://drstanfield.com/my-supplements/
Our bodies harbor countless microbes—and so do our tumors, it turns out. Over the past 5 years, researchers have shown cancer tissue contains entire communities of bacteria and fungi. Now, it appears some of the bacteria may be cancer’s accomplices. In a paper in this week, a team led by Susan Bullman of the Fred Hutchinson Cancer Center reports that in oral and colorectal tumors, bacteria live inside cancer cells and boost their production of proteins known to suppress immune responses. The microbial interlopers may set off a chain reaction that prevents the immune system from killing cancerous cells, and they may also help cancer metastasize to other parts of the body.
The study doesn’t entirely clinch the case for a bacterial role in cancer, but it is very suggestive, says Laurence Zitvogel, a tumor immunologist at the Gustave Roussy Institute. “It shows that bacteria in colorectal and oral tumors can actively disturb the immune equilibrium,” she says.
Confirmation that microbes can cause tumors to grow or spread could open up new ways to make cancer treatment more effective, for instance by killing bacteria with antibiotics. And because each type of cancer appears to come with a unique microbiome, researchers are exploring whether microbes could be used as a diagnostic tool to detect cancer early in a blood sample.
Engineered immune cells, known as CAR T cells, have shown the world what personalized immunotherapies can do to fight blood cancers. Now, investigators have reported highly promising early results for CAR T therapy in a small set of patients with the autoimmune disease lupus. Penn Medicine CAR T pioneer Carl June, MD, and Daniel Baker, a doctoral student in Cell and Molecular Biology in the Perelman School of Medicine at the University of Pennsylvania, discuss this development in a commentary published today in Cell.
“We’ve always known that in principle, CAR T therapies could have broad applications, and it’s very encouraging to see early evidence that this promise is now being realized,” said June, who is the Richard W. Vague Professor in Immunotherapy in the department of Pathology and Laboratory Medicine at Penn Medicine and director of the Center for Cellular Immunotherapies at Penn’s Abramson Cancer Center.
T cells are among the immune system’s most powerful weapons. They can bind to, and kill, other cells they recognize as valid targets, including virus-infected cells. CAR T cells are T cells that have been redirected, through genetic engineering, to efficiently kill specifically defined cell types.